Pruritus Therapeutic Market Report 2026

The pruritus therapeutic market size has grown strongly in recent years. It will grow from $15.38 billion in 2025 to $16.76 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing prevalence of dermatological and systemic conditions, wider use of antihistamines and corticosteroids, expansion of outpatient dermatology services, growing patient awareness of itch-related disorders, availability of diverse therapeutic options.

The pruritus therapeutic market size is expected to see strong growth in the next few years. It will grow to $24.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing investment in novel itch-modulating therapies, rising focus on personalized pruritus treatment, expansion of biologic and immunomodulatory drug pipelines, growing demand for non-steroidal therapies, increasing clinical research activity. Major trends in the forecast period include increasing development of targeted antipruritic drugs, rising adoption of combination drug therapies, growing focus on disease-specific pruritus management, expansion of advanced topical formulations, enhanced emphasis on long-term symptom relief.

The rising incidence of chronic kidney disease is expected to drive the growth of the pruritus therapeutic market in the coming years. Chronic kidney disease is a long-term condition in which kidney function gradually declines over time and is classified into five stages based on severity. Pruritus, commonly referred to as itching, is a frequent symptom experienced by patients with chronic kidney disease, although the exact underlying mechanisms are not fully understood. For example, in June 2023, according to Kidney Research UK, a UK-based charitable organization focused on kidney disease research and advocacy, approximately 7.19 million people in the UK were affected by chronic kidney disease in 2023, accounting for more than 10% of the population, and this number is projected to rise to 7.61 million by 2033. Therefore, the increasing prevalence of chronic kidney disease is contributing to the expansion of the pruritus therapeutic market.

Major companies operating in the pruritus therapeutic market are increasingly pursuing strategic partnerships to address moderate-to-severe atopic dermatitis. Strategic partnerships involve companies collaborating to combine resources, expertise, and capabilities to achieve shared objectives. For instance, in January 2023, Amgen Inc., a US-based biopharmaceutical company, in collaboration with Kyowa Kirin, began investigating rocatinlimab (AMG 451/KHK4083), a potential first-in-class anti-OX40 monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis. The companies initiated enrollment for a global Phase 3 clinical trial program, known as ROCKET, to evaluate the safety and efficacy of rocatinlimab in patients with heterogeneous moderate-to-severe atopic dermatitis and high disease burden. The ROCKET Phase 3 program comprises seven global studies. Kyowa Kirin Co., Ltd. is a Japan-based pharmaceutical and biotechnology company.

In March 2023, Ipsen, a France-based biopharmaceutical company, acquired Albireo Pharma, Inc. for an undisclosed amount. This acquisition strengthened Ipsen’s portfolio by adding innovative therapies for rare cholestatic liver diseases in both pediatric and adult patients, along with new pipeline opportunities and enhanced technical and financial capabilities. Albireo Pharma, Inc. is a US-based biopharmaceutical company focused on developing and commercializing novel bile acid modulators for the treatment of orphan pediatric liver disorders, gastrointestinal diseases, and pruritus-related conditions.

Major companies operating in the pruritus therapeutic market are Astellas Pharma Inc., Bristol Myers Squibb Company, Cipla Inc., Eli Lilly And Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck And Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Huapont Life Sciences Co. Ltd., LEO Pharma AS, MC2 Therapeutics Ltd., Novan Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd.

North America was the largest region in the pruritus therapeutic market in 2025. The regions covered in the pruritus therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pruritus therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pruritus therapeutic market by raising costs of imported pharmaceutical ingredients, excipients, drug delivery systems, and dermatology-focused medical devices. Healthcare providers in North America and Europe are most affected due to reliance on imported formulations, while Asia-Pacific faces cost pressures in generic drug manufacturing and export activities. These tariffs are increasing drug prices and impacting treatment accessibility. At the same time, they are supporting local pharmaceutical production, regional formulation development, and domestic supply chain strengthening for antipruritic therapies.

The pruritus therapeutic market research report is one of a series of new reports that provides pruritus therapeutic market statistics, including pruritus therapeutic industry global market size, regional shares, competitors with a pruritus therapeutic market share, detailed pruritus therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the pruritus therapeutic industry. This pruritus therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pruritus therapeutics refer to the treatment of pruritus, which is an uncomfortable sensation that triggers the urge to scratch. Pruritus can arise from various causes, including exposure to allergens, dry skin, pregnancy, and adverse reactions to medications.

The main therapeutic types used to manage pruritus include corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressants, calcineurin inhibitors, and other treatments. Corticosteroids are anti-inflammatory medications that closely resemble cortisol, a hormone naturally produced by the adrenal glands. Pruritus therapeutics are applied across several disease types, including atopic dermatitis or eczema, allergic contact dermatitis, urticaria, cutaneous T-cell lymphoma, and others. These treatments are administered through topical application, oral formulations, and injections, and are used in healthcare settings such as hospitals, clinics, and other facilities.

The pruritus therapeutic market includes revenues earned by entities by treating pruritus conditions with medicines such as aloe vera, menthol and petroleum jelly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.